GE cuts some debt using proceeds from sale of biopharma business
Reuters
Published Apr 13, 2020 09:54AM ET
(Reuters) - General Electric Co (N:GE) said on Monday it used part of the $20 billion in proceeds from the sale of its biopharma business to cut debt.
The U.S. industrial conglomerate last week pulled its full-year forecast due to the uncertainties created by the coronavirus outbreak, but backed its first-quarter industrial free cash flow expectation of near-negative $2 billion.
GE has repaid $6 billion of its intercompany loan to finance arm GE Capital on April 1 using funds from the biopharma proceeds, it said on Monday.
The company's total borrowings stood at $90.9 billion as of Dec. 31.
GE Capital launched a tender targeting up to $9 billion of debt maturing in 2020, GE said, using the repayment amount. The unit also repaid $4.7 billion of debt that matured in the first quarter of 2020.
GE, which makes jet engines, power plants and other industrial equipment, last month sold its biopharma business to Danaher Corp (N:DHR) to focus on its core aviation and power businesses.
GE held cash, cash equivalents, and restricted cash of more than $47 billion as of March 31.
The company said that it was launching a strategic debt issuance to fund an immediate tender for GE bonds maturing through 2024, and has also refinanced a back-up credit facility that expires in 2021.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.